• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Circassia

edit

Circassia is a specialty biopharmaceutical company focused on developing a new class of T-cell vaccines designed to treat allergies and combat organ transplant rejection. The Company’s most advanced allergy T-cell vaccine is entering late-stage development, having successfully completed a number of phase II clinical studies.

Recent Milestones

edit

• 
  Circassia received $98M in Series D funding. (4/19/11)
  Posted 4/19/11 at 6:28pm via fiercebiotech.com
• 
  Circassia received $24.8M (£15.3M) in Series C funding. (12/14/09)
  Posted 12/11/09 at 10:24pm via dowjones.com
• 
  Circassia added Steven Harris as CEO.
  Posted 12/11/09 at 10:24pm
• 
  Circassia added Charles Swingland as Deputy Chairman and General Counsel.
  Posted 12/11/09 at 10:24pm

Videos

Screenshots

edit

Above: Home Page
Uploaded: 12/12/09

Sources

1. Cat Allergy Treatment Co. Circassia Nabs $25M, Takes Gander At Dander (fis.dowjones.com) [edit]
2. Circassia lands $98M venture round as it plots Ph3 trials (fiercebiotech.com) [edit]